These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20386440)

  • 21. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
    Terpening C
    J Am Board Fam Med; 2009; 22(1):51-6. PubMed ID: 19124633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL
    Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
    Raju NC; Eikelboom JW; Hirsh J
    Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
    Koziński M; Grześk G; Kubica J
    Kardiol Pol; 2012; 70(2):206-12. PubMed ID: 22427098
    [No Abstract]   [Full Text] [Related]  

  • 25. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
    Berger JS
    Am J Cardiol; 2013 Sep; 112(5):737-45. PubMed ID: 23751937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C
    Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747
    [No Abstract]   [Full Text] [Related]  

  • 28. Future of oral antiplatelet therapy: four challenged hypotheses.
    Serebruany VL; Makarov LM
    Thromb Haemost; 2009 Jun; 101(6):1041-3. PubMed ID: 19492145
    [No Abstract]   [Full Text] [Related]  

  • 29. Ticagrelor: a novel oral antiplatelet agent.
    Huang NS; Master HH; Fusco JA; Park ZH
    Consult Pharm; 2010 Nov; 25(11):745-55. PubMed ID: 21138823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
    Amsallem M; Manzo-Silberman S; Dillinger JG; Sideris G; Voicu S; Bal dit Sollier C; Drouet L; Henry P
    Am J Cardiol; 2015 May; 115(9):1305-10. PubMed ID: 25759104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
    Robinson A; Das K; Koshy SK; Das P
    Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A brief review of the past and future of platelet P2Y12 antagonist.
    Barn K; Steinhubl SR
    Coron Artery Dis; 2012 Sep; 23(6):368-74. PubMed ID: 22735090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facts and controversies of aspirin and clopidogrel therapy.
    Faxon DP; Freedman JE
    Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on oral antiplatelet therapy: principles, problems and promises.
    Grove EL; Kristensen SD
    Future Cardiol; 2009 May; 5(3):247-58. PubMed ID: 19450051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
    Sousa-Uva M; Storey R; Huber K; Falk V; Leite-Moreira AF; Amour J; Al-Attar N; Ascione R; Taggart D; Collet JP;
    Eur Heart J; 2014 Jun; 35(23):1510-4. PubMed ID: 24748565
    [No Abstract]   [Full Text] [Related]  

  • 38. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
    Wallentin L; Varenhorst C; James S; Erlinge D; Braun OO; Jakubowski JA; Sugidachi A; Winters KJ; Siegbahn A
    Eur Heart J; 2008 Jan; 29(1):21-30. PubMed ID: 18055486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
    Alexopoulos D; Xanthopoulou I; Davlouros P; Tsigkas G; Damelou A; Theodoropoulos KC; Gkizas V; Hahalis G
    J Thromb Haemost; 2013 Feb; 11(2):381-4. PubMed ID: 23216658
    [No Abstract]   [Full Text] [Related]  

  • 40. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.